1. Top of page
  2. Abstract
  7. Acknowledgements


In vitro activation of the receptor EphB4 positively affects human osteoarthritis (OA) articular cell metabolism. However, the specific in vivo role of this ephrin receptor in OA remains unknown. We investigated in mice the in vivo effect of bone-specific EphB4 overexpression on OA pathophysiology.


Morphometric, morphologic, and radiologic evaluations were performed on postnatal day 5 (P5) mice and on 10-week-old mice. Knee OA was induced surgically by destabilization of the medial meniscus (DMM) in 10-week-old male EphB4 homozygous transgenic (EphB4-Tg) and wild-type (WT) mice. Medial compartment evaluations of cartilage were performed using histology and immunohistochemistry, and evaluations of subchondral bone using histomorphometry, osteoclast staining, and micro–computed tomography.


There was no obvious phenotype difference in skeletal development between EphB4-Tg mice and WT mice at P5 or at 10 weeks. At 8 and 12 weeks post-DMM, the EphB4-Tg mice demonstrated significantly less cartilage alteration in the medial tibial plateau and the femoral condyle than did the WT mice. This was associated with a significant reduction of aggrecan and type II collagen degradation products, type X collagen, and collagen fibril disorganization in the operated EphB4-Tg mice. The medial tibial subchondral bone demonstrated a significant reduction in sclerosis, bone volume, trabecular thickness, and number of tartrate-resistant acid phosphatase–positive osteoclasts at both times assessed post-DMM in the EphB4-Tg mice than in the WT mice.


This is the first in vivo evidence that bone-specific EphB4 overexpression exerts a protective effect on OA joint structural changes. The findings of this study stress the in vivo importance of subchondral bone biology in cartilage integrity.

Osteoarthritis (OA) is the most common form of arthritis and a leading cause of long-term disability. With increasing life expectancy, OA is a major socioeconomic and clinical concern, as no curative treatment yet exists. While considerable advancement has been made toward a better understanding of the pathophysiology of the disease process, there is still much to be accomplished before a disease-modifying OA drug is developed that can effectively reduce or stop the disease progression. It is therefore of the utmost importance to identify new candidates that can contribute to the development of therapeutic agents to prevent or arrest the disease process.

Although the hallmark of OA is the progressive degeneration of articular cartilage, the subchondral bone is also suggested to be an active component of the OA process in humans (1–4). The rationale is that because the subchondral bone plate is in direct contact with the cartilage, it influences not only mechanical effects, but also cartilage degradation by providing catabolic factors to this overlying tissue, thus promoting abnormal cartilage metabolism. The presence of clefts or channels in the tidemark during the OA process, as well as microcracks between the subchondral bone region and the uncalcified cartilage and vascularization in the subchondral bone, could favor a diffusion of factors from the subchondral bone region to the basal layer of cartilage and be responsible for the remodeling in the deep zone of OA articular cartilage.

The concept that the subchondral bone and cartilage should be considered an interdependent functional unit is gaining strong support, as illustrated by in vitro studies in which human OA subchondral bone osteoblasts demonstrated abnormal metabolism, including elevated levels of some bone markers and factors involved in bone biology (5–8). These findings are also consistent with the in vivo observations in animals (2, 9–11) and in knee OA patients (12–16), demonstrating such interdependence between the loss of cartilage and the deterioration of the subchondral bone structure. These and other findings strengthen the hypothesis that changes in subchondral bone play a key role in the genesis of cartilage lesions during OA.

In the musculoskeletal system, recent studies suggest the involvement of the receptor erythropoietin-producing hepatocellular B4 (EphB4) and its specific ligand, ephrin B2, in bone biology (17–21). The Eph receptors and their ephrin ligands constitute the largest subfamily of membranous receptor tyrosine kinases. The ephrin/Eph signaling depends on their expression/production and on the nature of the interacting/targeting cell types. Ephrins were originally identified as axon guidance molecules that mediate neuron repulsion during central nervous system development. They were since shown to regulate a variety of tissues and cell types and to act on cells, resulting in a myriad of biologic functions. Interestingly, a major common role is the control of extracellular matrix remodeling. The first member of the Eph family was identified and cloned in 1987 and, to date, 14 receptors and 8 ligands have been described in mammals. Eph receptors are grouped into two subclasses (A and B) according to their ligand (ephrin A or B) specificity.

In bone, osteoclasts express ephrin B1 and ephrin B2 without any detectable EphB receptors (17), while osteoblasts express both ephrin B2 and EphB4 receptors (18, 22). Of note, ephrin B2 is the sole ligand for the EphB4 receptor. The ephrin B2/EphB4 system was also recently reported to be present in another articular tissue, the cartilage (23). In vitro data revealed that ephrin B2 activation positively affects some abnormal metabolism in human OA subchondral bone osteoblasts and chondrocytes (22, 23). Briefly, these in vitro studies suggest that in human OA, EphB4 receptor activation could act at two different levels: by limiting the extent of matrix degradation in both cartilage and subchondral bone, and by regulating the abnormal osteoclastogenesis process in the subchondral bone and anabolism in cartilage, indicating that this system could be an interesting therapeutic target for OA. Collectively, these data suggest that enhancing the activation of this system could impart a protective effect on the structural changes in these articular tissues. Further in vivo studies are therefore essential to complement our understanding of the role of ephrin B2/EphB4 in articular tissues.

This study thus aimed to determine the in vivo effect of the EphB4 receptor in the pathophysiology of OA. As evidence suggests the subchondral bone to be an active component of the OA process, we investigated the in vivo effect of bone-specific overexpression of EphB4 receptors on OA development in mice.


  1. Top of page
  2. Abstract
  7. Acknowledgements

Bone-specific EphB4 receptor–overexpressing mice.

The model used in this study was a transgenic mouse in which EphB4 is overexpressed under the control of the mouse Col1 promoter (17). Briefly, mouse Ephb4 complementary DNA was subcloned upstream of the osteoblast-specific promoter region of the mouse proα1(1) collagen gene. The Nar l–Sal l fragment containing the 2.3-kb proα1(1) promoter Ephb4 coding–region poly(A) signal was isolated and microinjected into pronuclei of fertilized eggs from B6C3F1 (C57BL/6 × C3H1/He) females.

We bred 2 transgenic EphB4/Col1 heterozygous couples. Routine genotyping was carried out on DNA from ear punch biopsy samples using specific primers. Genomic DNA was isolated with DirectPCR lysis reagent containing proteinase K (Viagen Biotech) according to the manufacturer's instructions. The polymerase chain reaction (PCR) was performed on the genomic DNA using the following primers: 5′-GCATGAGCCGAAGCTAACCC-3′ (Col1α1) and 5′-CTTTGATTTGCACCACCACCGGAT-3′ (primer of the vector to which EphB4 is attached, pNASSβ). GAPDH was used as the reference gene (5′-CACAGTCCATGCCATCAC-3′ and 5′-GATCCACGACGGACACATTG-3′). Zygosity was determined by comparing by real-time quantitative PCR the transgene expression to the reference gene (GAPDH) according to the method of Shitara H et al (24). Briefly, the relative quantification performed with the 2math image method determined the zygosity, yielding 0 wild-type, ≥1 heterozygous, and ≥2 homozygous mice.

Transgene overexpression protein production was also confirmed by Western blotting. Briefly, osteoblasts were released from long bones by sequential enzymatic digestion at 37°C, and cells were seeded in Ham's F-12/Dulbecco's modified Eagle's medium (Wisent) supplemented with 10% heat-inactivated fetal bovine serum (PAA Laboratories) and an antibiotic mixture and incubated at 37°C in a humidified atmosphere until confluence. Cell lysates were solubilized in sample buffer (62.5 mM Tris HCl, 10% glycerol, 5% 2-mercaptoethanol, and 2% sodium dodecyl sulfate), and evaluation was performed by Western blotting, as previously described (25), using mouse EphB4 affinity-purified polyclonal goat antibody (1:5,000 dilution; R&D Systems). As a loading control, β-actin was used.

All procedures involving animals were performed according to regulations of the Canadian Council on Animal Care and were approved by the Animal Care Committee of the University of Montreal Hospital Centre. All mice were maintained under a 12-hour light/dark cycle. Food and water were available ad libitum.

Evaluation of knee joint swelling.

The operated mice (see below) were examined daily. The knee diameter was measured in the mediolateral plane every 3 days, using digital calipers (model 2071M; Mitutoyo), as previously described (25).

Skeleton morphology.

Morphologic evaluation of the mouse skeleton was performed with alizarin red and Alcian blue staining on postnatal day 5 (P5). Samples were fixed in 70% ethanol (24 hours) and then placed in 100% acetone (24 hours). Skeletons were then stained with a mixture of 0.05% alizarin red, 0.015% Alcian blue, and 5% acetic acid, placed in 2% potassium hydroxide until clear, and stored in 70% ethanol and glycerol (1:1) as described previously (26, 27).

Radiographic imaging.

High resolution radiographs of 10-week-old mice were obtained with a Faxitron model MX-20 machine equipped with an FPX-2 imaging system (MedOptics/DALSA Life Sciences). Radiographs were used to qualitatively assess bone morphology.

Surgically induced OA mouse model.

OA was surgically induced in 10-week-old male EphB4 homozygous and wild-type (WT) mice by destabilization of the medial meniscus (DMM) in the right knee, as previously described (28). The mice were anesthetized with isoflurane and O2, and the right knee joint was destabilized by transection of the anterior attachment of the medial meniscus to the tibial plateau. A sham operation, which involved a similar incision to the knee without compromising the joint capsule, was also performed on the right knee of 10-week-old WT mice and 10-week-old mice overexpressing EphB4. Mice were observed daily to verify healing and to ensure that they were using their right limb.



Operated mice were euthanized at 8 and 12 weeks after surgery, nonoperated control mice at an equivalent age, and sham-operated mice at 12 weeks postsurgery. The right knee joints were dissected free of tissue, fixed in TissuFix (Chaptec), decalcified in RDO Rapid Decalcifier (Apex Engineering), and embedded in paraffin, as previously described (25). Sections (5 μm) were deparaffinized in xylene, followed by a graded series of alcohol washes, and stained with Safranin O–fast green (Sigma-Aldrich). Two independent observers who were blinded with regard to group allocation graded the severity of the OA lesions using the Osteoarthritis Research Society International (OARSI) scoring method (29). Three sections were prepared from each block, each slide was examined, and the final score was a consensus between the 2 observers.

Collagen disorganization.

Collagen disorganization was evaluated on 5-μm paraffin sections following sirius red staining, as described elsewhere (30, 31). Two independent observers who were blinded with regard to group allocation graded the severity of collagen disorganization under polarized light microscopy using a modified scale of 0–2, where 0 = normal cartilage, 1 = partial disorganization, and 2 = total disorganization. Three areas were evaluated, and the scores summed (maximum score 6).


The right knee joints were dissected, fixed in 4% paraformaldehyde for 16 hours at 4°C, decalcified in 10% EDTA for 14 days at 4°C, and embedded in paraffin. Immunohistochemical analysis was performed on 5-μm paraffin sections. Briefly, sections were pretreated with 0.25 units/ml of protease-free chondroitinase ABC in phosphate buffered saline (PBS; Sigma-Aldrich), and 1% hyaluronidase in 0.1M Tris acetate (Sigma-Aldrich) for 60 minutes at 37°C. The specimens were incubated for 18 hours at 4°C with the following primary antibodies: goat polyclonal anti-EphB4 (1:100 dilution; R&D Systems), rabbit polyclonal anti–C-terminal peptide of aggrecan G1 domain (VDIPEN, 1:800 dilution; provided by Dr. J. S. Mort, Shriners Hospital for Children, McGill University Hospital Centre, Montreal, Quebec, Canada) (32), a rabbit polyclonal antibody that represents a type II collagen primary cleavage site (Col2-3/4Cshort, 1:200 dilution; provided by Dr. A. R. Poole, Shriners Hospital for Children, McGill University Hospital Centre, Montreal, Quebec, Canada) (33), and mouse anti–type X collagen antibody (1:100 dilution; provided by Dr. E. Lee, Shriners Hospital for Children, McGill University Hospital Centre, Montreal, Quebec, Canada) (34).

Each slide was washed 3 times in PBS (pH 7.4) and incubated with a secondary antibody using a Vectastain ABC kit (Vector) and following the manufacturer's instructions. The color was developed with 3,3′-diaminobenzidine containing hydrogen peroxide, and slides were counterstained with eosin and, for EphB4, with methyl green.

Control procedures were performed according to the same experimental protocol as follows: 1) omission of the primary antibody, 2) substitution of the primary antibody with a nonspecific IgG from the same host as the primary antibody (Santa Cruz Biotechnology), and 3) a third control for type X collagen was performed by adsorption with the peptide YNRQQHYDPRSGIFTCKIPGIYYFSYGGC (provided by Dr. E. Lee) at a 10-fold. Controls showed only background staining.

VDIPEN and Col2-3/4Cshort staining was graded on a scale of 0–3, where 0 = no staining, 1 = minor staining, 2 = marked staining, and 3 = maximal staining, as described previously (35). Each slide was examined and scored by 2 independent observers who were blinded with regard to group allocation. Type X collagen–expressing cells were quantified following determination of the total number of chondrocytes and the total number staining positive for the antigen. The final results were expressed as the percentage of chondrocytes staining positive for the antigen (cell score; maximum score 100%).

Subchondral bone.

Tartrate-resistant acid phosphatase (TRAP).

The right knee joints were dissected free of tissue, fixed in 4% paraformaldehyde for 16 hours at 4°C, decalcified in 10% EDTA for 14 days at 4°C, and embedded in paraffin. Staining for TRAP enzyme activity was carried out as previously described (36). Briefly, the deparaffinized and rehydrated sections were incubated in the staining medium containing naphthol AS-TR phosphate as substrate, pararosaniline HCl as the coupler, and N,N-dimethylformamide tartrate solution. Counterstaining was performed with 0.4% methyl green. Negative staining was performed without substrate.

To determine the number of osteoclasts, the subchondral bone area that was evaluated comprised the cartilage–bone junction and the growth plate as the upper and lower limits. The analysis was performed on 1 section per specimen using a Leitz Diaplan microscope (Leica Microsystems) connected to a personal computer (Pentium IV based, using Bioquant Osteo II Image Analysis software), as previously described (11, 25, 37). Data are expressed as the number of cells expressing TRAP per subchondral bone surface (mm2).

Subchondral bone plate histomorphometry.

The right knee joints were fixed in TissuFix, decalcified in RDO Rapid Decalcifier, embedded in paraffin, and sections (5 μm) were deparaffinized in xylene followed by a graded series of alcohol washes and then stained with Safranin O–fast green as described above. Histomorphometry was done on the medial compartment, as described elsewhere (11), using a Leitz Diaplan microscope connected to a personal computer as above. From the digital image, a box with a fixed width (1,000 μm) and variable length was created with the upper limit at the calcified cartilage–subchondral bone junction and the lower limit at the subchondral bone–trabecular bone junction. The mean distance between the upper and lower limit was calculated automatically by the software. All measurements were made by a single experienced observer who was blinded with regard to the experimental conditions.

Micro–computed tomography (micro-CT).

Prior to sectioning, the right femoral distal metaphysis and tibial proximal metaphysis were scanned with a SkyScan 1176 in vivo micro-CT instrument. Image acquisition was performed at 72 keV and 142 μA, with a 0.6° rotation between frames through a total of 180°, and at 9 μm spatial resolution. Two dimensional (2-D) images were used to generate 3-D reconstructions of the trabecular subchondral bone. For the subchondral bone, 15 reconstructed grayscale images were selected from immediately above the tibial growth plate, and 3-D analysis was used to calculate morphometric parameters in the medial compartment, including the volume fraction (bone volume/total volume; %), trabecular thickness (mm), and trabecular separation (μm) at the same threshold with the 3D Creator software supplied with the SkyScan CT Analyzer.

Statistical analysis.

Values are expressed as mean ± SEM. Statistical analysis was performed using the Mann-Whitney U test (GraphPad Prism software).


  1. Top of page
  2. Abstract
  7. Acknowledgements

All data reported herein are from experiments performed on male mice. However, characterization of the zygosity done on the females revealed the same findings (data not shown).

Characterization of the EphB4-transgenic mice.

The offspring of the breeding animals were genotyped using PCR analysis. As illustrated in Figure 1A, the data showed the 193-bp band in homozygous mice, but not WT mice. The parent mice and their subsequent generations were further genotyped by quantitative PCR (Figure 1B). Significant differences in zygosity were obtained when heterozygous and homozygous mice were compared to the WT control mice (P ≤ 0.005). Additional Western blot experiments (Figure 1C) confirmed the overproduction of EphB4 protein in long bone osteoblasts from heterozygous mice, more so in those from homozygous mice, as compared to WT mice. Further experiments were carried out using homozygous transgenic EphB4 (EphB4-Tg) mice and their WT littermates (controls).

thumbnail image

Figure 1. Genotyping of bone-specific EphB4–overexpressing mice. A, Representative polymerase chain reaction (PCR) analysis of transgene expression in 2 wild-type (WT; control) mice and 2 homozygous bone-specific EphB4–overexpressing mice. GAPDH was used as the reference gene. B, Quantitative PCR analysis showing EphB4 expression levels in WT (n = 9), heterozygous (n = 9), and homozygous (n = 6) mice as compared to those in 1 set of bone-specific EphB4–overexpressing heterozygous parents. Values are the mean ± SEM. P values were determined by Mann-Whitney U test. C, Representative Western blots comparing EphB4 protein levels in osteoblasts obtained from WT mice with those obtained from heterozygous and homozygous bone-specific EphB4–overexpressing mice. Osteoblasts were released as described in Materials and Methods, and cell lysates were processed for Western blotting using specific EphB4 and β-actin antibodies. Bands of 120 kd and 43 kd were found for EphB4 and β-actin, respectively. The ratio represents the values of EphB4 over β-actin for each condition.

Download figure to PowerPoint

Morphometric assessment of 5-day-old (P5) mice showed that the EphB4-Tg mice were similar in body size and gross appearance to the WT mice (Figure 2A). Skeletal staining showed no significant differences in the growth and development of the mice (Figure 2B). The body weight of the male mice examined at P3 (25 WT and 29 EphB4-Tg mice), P10 (25 WT and 28 EphB4-Tg mice), P28 (28 WT and 23 EphB4-Tg mice), and P70 (8 WT and 8 EphB4-Tg mice) also showed no change across the genotype until at least 10 weeks of age (data not shown). Similarly, at the age of 10 weeks, mice demonstrated no difference in size or weight morphologically (Figure 2C). However, radiographic evaluation showed an increase in the femur density in the EphB4-Tg mice as compared to the WT mice (Figure 2D). Overexpression of EphB4 in transgenic osteoblasts was confirmed by immunohistochemistry, in which the staining per osteoblast was more enhanced in the EphB4-Tg mice (Figure 2E). However, when compared to WT mice, no significant differences in osteoblasts per bone surface were seen in subchondral bone from EphB4-Tg mice by 10 weeks of age.

thumbnail image

Figure 2. Morphometric, morphologic, radiographic, and EphB4 immunohistochemical assessments of wild-type (WT) mice and bone-specific EphB4–overexpressing transgenic (EphB4-Tg) mice. A and B, Representative WT and EphB4-Tg mice on postnatal day 5 (P5), showing similar size and gross appearance (A) as well as similar skeletal development (B). C–E, Representative morphologic (C), radiographic (D), and EphB4 immunohistochemical (E) features of 10-week-old male WT and EphB4-Tg mice. Arrow in D indicates a higher density of the femur in the EphB4-Tg mouse as compared to the WT mouse. Arrows in E show enhanced osteoblast staining in the EphB4-Tg mouse as compared to the WT mouse. Bar in E = 50 μm; original magnification × 400.

Download figure to PowerPoint

Knee joint swelling.

Knee joint swelling was determined by the diameter of the operated (right) knee in WT and EphB4-Tg mice at 8 (WT, n = 10; EphB4-Tg, n = 10) and 12 (WT, n = 20; EphB4-Tg, n = 20) weeks post-DMM surgery. Mice were examined at baseline (day 0) and every 3 days following surgery. Data showed that the initial swelling following surgery receded similarly in both WT and EphB4-Tg mice; this was true for mice sacrificed at 8 and 12 weeks postsurgery (data not shown).

Significant resistance of EphB4-Tg mice to OA cartilage alterations post-DMM surgery.

The cartilage integrity in the medial tibial plateau and femoral condyle at 8 and 12 weeks post-DMM surgery was assessed histologically and scored according to the OARSI scoring system (29). First, we compared the histology scores for the medial tibial plateau and femoral condyle from the sham-operated EphB4-Tg mice (mean ± SEM 0.7 ± 0.3 and 1.0 ± 0.0, respectively; n = 3) and the WT control mice (1.3 ± 0.6 and 1.3 ± 0.6, respectively; n = 3) to those from 22-week-old nonoperated mice from both groups (1.0 ± 0.0 and 0.7±0.6, respectively, in EphB4-Tg mice [n = 3]; 1.0 ± 0.0 and 0.7 ± 0.3, respectively, in WT mice [n = 6]). The data revealed no significant differences among these control groups.

As illustrated in Figures 3A–D, the medial tibial plateaus and femoral condyles of DMM-operated WT mice at both times postsurgery showed an increased loss of cartilage integrity, including loss of Safranin O–fast green staining, accompanied by reduced cellularity, thinning of the cartilage, and increased fibrillation as compared to the DMM-operated EphB4-Tg mice. These observations were corroborated by the OARSI scores (Figures 3E–H), which showed significantly lower histologic scores in the DMM-operated EphB4-Tg mice at 8 weeks (P ≤ 0.006 and P ≤ 0.01, respectively) and 12 weeks (P ≤ 0.01 and P ≤ 0.03, respectively) postsurgery.

thumbnail image

Figure 3. A–D, Photomicrographs of representative histologic sections of the medial tibial plateaus (T) and femoral condyles (F) obtained from wild-type (WT) mice and bone-specific EphB4–overexpressing transgenic (EphB4-Tg) mice at 12 weeks after sham surgery or surgery to destabilize the medial meniscus (DMM). Arrows in C indicate areas of fibrillation, with loss of chondrocytes, and Safranin O–fast green staining, indicating loss of aggrecan. White lines delineate the subchondral bone plate thickness. Bar in A = 100 μm; original magnification × 100. E–H, Histologic scores in the medial tibial plateaus and medial femoral condyles from WT mice and EphB4-Tg mice at 8 weeks and 12 weeks after DMM surgery, as determined using the Osteoarthritis Research Society International (OARSI) scoring system. Values are the mean ± SEM of 8 mice per group, except for EphB4-Tg mice at 12 weeks, which used 7 mice. P values were determined by Mann-Whitney U test.

Download figure to PowerPoint

Protective effect of some cartilage markers in EphB4-Tg mice.

In DMM-operated mice at 8 and 12 weeks postsurgery, the effect of EphB4 overexpression on the degradation products of aggrecan (Figure 4A) and on type II collagen (Figure 4B) and type X collagen (Figure 4C) was examined using specific antibodies, and the effect on collagen disorganization (Figure 4D) was examined using the sirius red method. Data are reported only for 12 weeks post-DMM surgery, but similar data were found at 8 weeks post-DMM surgery. DMM-operated EphB4-Tg mice demonstrated significantly reduced levels of aggrecan fragments (P ≤ 0.04), in the α1 chain of type II collagen (P ≤ 0.008), and collagen disorganization in the medial tibial plateau (P ≤ 0.0008) at 12 weeks postsurgery (Figures 4A, B, and D). In addition, the medial femoral condyle exhibited a significant decrease in aggrecan degradation products (P ≤ 0.04) (Figure 4A); however, data obtained for the type II collagen degradation products (Figure 4B) and for collagen disorganization (Figure 4D) showed no significant difference. Type X collagen (Figure 4C), which is associated with chondrocyte hypertrophy, also showed significantly lower levels in both the tibial plateau (P ≤ 0.009) and femoral condyle (P ≤ 0.02) in DMM-operated EphB4-Tg mice as compared to the DMM-operated WT mice.

thumbnail image

Figure 4. Photomicrographs of representative immunohistologic and stained sections of cartilage (left) and corresponding histology scores in the medial tibial plateaus and femoral condyles (right) obtained from wild-type (WT) mice and bone-specific EphB4–overexpressing transgenic (EphB4-Tg) mice at 12 weeks following surgery to destabilize the medial meniscus. Degradation products of aggrecan (VDIPEN; n = 7 mice per group) (A), type II collagen (Col2-3/4Cshort; n = 7–8 mice per group) (B), type X collagen (n = 5 WT mice and n = 6 EphB4-Tg mice) (C), and collagen disorganization as assessed with sirius red staining (n = 7–8 mice per group) (D) are shown. Arrows in B indicate extracellular staining. White vertical bars in D indicate the cartilage thickness. The negative controls were as follows: for VDIPEN and the Col2-3/4Cshort, substitution of a nonspecific rabbit IgG for the primary antibody, and for type X collagen, adsorption with the specific peptide. Bars = 100 μm; original magnification × 250. Values for the histology scores are the mean ± SEM. P values were determined by Mann-Whitney U test.

Download figure to PowerPoint

Better preserved subchondral bone in EphB4-Tg mice.

Representative histology sections of the subchondral bone plate thickness from the sham-operated WT mice and the EphB4-Tg mice at 12 weeks postsurgery are shown in Figures 3A–D. Histomorphometric evaluation of the subchondral bone plate thickness demonstrated similar values for the sham-operated WT and EphB4-Tg mice at both 8 weeks (data not shown) and 12 weeks post-DMM surgery (Figure 5A). Compared to sham-operated mice at 12 weeks postsurgery, the subchondral bone plate thickness at 8 weeks and 12 weeks postsurgery was significantly increased in the WT (P ≤ 0.01) and EphB4-Tg (P ≤ 0.05) DMM-operated mice (Figure 5A). However, the DMM-operated EphB4-Tg mice demonstrated a statistically significant decrease in subchondral bone plate thickness compared to the DMM-operated WT mice at both 8 weeks (P ≤ 0.007) and 12 weeks (P ≤ 0.003) postsurgery (Figure 5A).

thumbnail image

Figure 5. A, Histomorphometric analysis of the subchondral bone of the medial tibial plateau in wild-type (WT) mice and bone-specific EphB4–overexpressing transgenic (EphB4-Tg) mice. The subchondral bone plate thickness was assessed at 12 weeks in the sham-operated mice (n = 3 mice per group) and at 8 weeks and 12 weeks in the mice with a surgically destabilized medial meniscus (DMM; n = 8 mice per group). B–E, Photomicrographs of representative sections of subchondral bone stained with tartrate-resistant acid phosphatase (TRAP) obtained at 12 weeks after DMM surgery. Boxed areas in B and D (original magnification × 100) are shown at higher magnification in C and E, respectively (original magnification × 400). Arrows indicate TRAP-positive osteoclasts. Bars in B and C = 100 μm. F, Numbers of osteoclasts in the subchondral bone at 12 weeks post-DMM surgery in WT mice (n = 6) and EphB4-Tg mice (n = 5), as determined by TRAP analysis. Values in A and F are the mean ± SEM. P values were determined by Mann-Whitney U test.

Download figure to PowerPoint

TRAP analysis revealed significantly lower numbers of osteoclasts in the EphB4-Tg mice than in the WT mice (P ≤ 0.009) at 12 weeks postsurgery (Figures 5B–F).

The 3-D rendering and reconstruction scans of WT mice at 12 weeks postsurgery (Figure 6A) showed alterations of the knee joint, including the thickness of the medial subchondral plate and pronounced sclerosis of the subchondral bone, while the EphB4-Tg mice (Figures 6B) demonstrated fewer changes. Comparison of the WT and EphB4-Tg sham-operated mice 12 weeks postsurgery revealed similar findings for the subchondral bone parameters (Figures 6C–E). However, DMM-operated WT mice had a significant increase in bone volume (P ≤ 0.02) and trabecular thickness (P ≤ 0.02) compared to the sham-operated mice. Moreover, at 12 weeks post-DMM surgery, the EphB4-Tg mice exhibited significantly reduced bone volume and trabecular thickness (P ≤ 0.0007 and P ≤ 0.02, respectively) compared to the WT mice (Figures 6C and D). There were similar values for trabecular separation (Figure 6E) in both the operated WT and EphB4-Tg mice at 12 weeks post-DMM surgery, and no difference was found as compared to their sham-operated controls.

thumbnail image

Figure 6. A and B, Micro–computed tomography of the subchondral bone of the tibial plateau in wild-type (WT) and bone-specific EphB4–overexpressing transgenic (EphB4-Tg) mice. Representative 2-dimensional (2-D) reconstructions of the lateral and medial subchondral bone compartment (top) and 3-D model of the medial subchondral bone compartment (bottom) at 12 weeks following sham surgery or surgery to destabilize the medial meniscus (DMM) are shown. Also included are the representative 2-D (top right) and 3-D (bottom right) reconstructions of the knee joints at 12 weeks post-DMM surgery. Arrow in the 2-D reconstruction of the knee joint indicates increased sclerosis of the subchondral bone plate in the WT mouse as compared to the EphB4-Tg mouse. C–E, Assessment of the bone volume/total volume (BV/TV), trabecular thickness, and trabecular separation at 12 weeks postsurgery in sham-operated mice (n = 3 mice per group) and mice subjected to DMM surgery (n = 6 WT mice and n = 8 EphB4-Tg mice). Values are the mean ± SEM. P values were determined by Mann-Whitney U test.

Download figure to PowerPoint


  1. Top of page
  2. Abstract
  7. Acknowledgements

This study is the first to delineate in vivo the role of the EphB4 receptor in articular tissues during the development of OA, using bone-specific EphB4 receptor–overexpressing mice. Our data demonstrated that bone-specific overexpression of EphB4 exerted a protective effect in OA not only on the subchondral bone, but also on the cartilage structure as well as on some tissue markers of the disease.

The findings of this in vivo study support the hypothesis that protecting the subchondral bone prophylactically reduces the severity of cartilage lesions during the OA process. Indeed, although it was shown that during the OA process, there is a remodeling of the subchondral bone that results in sclerosis, recent studies reported in the literature showed that this pathologic tissue demonstrates abnormal mineralization and, consequently, hypomineralization associated with a lower tissue modulus, which adversely affects the capacity of adjacent articular cartilage to adapt to mechanical loads (38–42). In turn, this will lead to cartilage damage, and be at least partly responsible for the evolution of cartilage lesions during the disease.

This study first showed that the EphB4-Tg mice have normal skeletal development and body weight at birth. Our data are also consistent with the characterization reported by Zhao et al (17), in that although the EphB4-Tg mice cannot be differentiated morphologically, radiographic evaluation showed an increase in long bone density, a decrease in TRAP-positive cells in subchondral bone, an enhanced staining of the EphB4 receptor in bone, and no significant differences in osteoblasts per bone surface by 10 weeks of age as compared to WT mice.

The OA model chosen was surgical DMM of the right knee, which induces mild-to-moderate OA lesions (28). Only males were used, since this sex develops better characteristics of the disease (28). The data demonstrated in the DMM-operated mice a transient joint swelling following surgery, possibly reflecting wound healing, with a further similar decline in the WT controls and EphB4-Tg mice. These findings are strongly indicative that bone EphB4 overexpression has little involvement in the process of inflammation during OA. However, as this OA model did not show appreciable synovitis as reported by Glasson et al (28), the implication of EphB4 in synovial inflammation requires additional studies in which another OA model with more synovitis is used.

It is well known that during the OA process in humans, the subchondral bone becomes sclerotic. The same was seen in the DMM-operated WT mice, in which sclerosis of the subchondral bone was found at the medial tibial plateau by histologic assessment and micro-CT analysis. This finding is consistent with data from a more advanced stage of the disease using the DMM model of OA (25, 43) and other OA animal models (44–47). However, our data on the micro-CT features of the subchondral bone in control mice (sham), which showed no significant differences in bone volume between EphB4-Tg and WT mice, are in contrast to those of Zhao et al (17), which showed an increase in bone volume in the trabecular bone. This difference could be explained by the fact that the subchondral bone and the trabecular bone respond differently, since they are both structurally and functionally different.

In the DMM-operated EphB4-Tg mice, the subchondral bone plate thickness, trabecular bone volume and thickness, and osteoclast numbers were significantly decreased compared to the DMM-operated WT, indicating that the EphB4-Tg mice demonstrated a better preservation of the subchondral bone structure following surgery. These findings suggest a role of EphB4 in preserving subchondral bone during OA and are consistent with the findings of an in vitro study of human OA subchondral bone osteoblasts, in which ephrin B2–activating EphB4 receptors inhibited various catabolic mediators that may have acted to limit the abnormal metabolism of this tissue (22).

These changes in the subchondral bone were associated with significantly less cartilage damage in the DMM-operated EphB4-Tg mice than in the WT mice at both times examined. These data strongly support the hypothesis that preserving the subchondral bone properties positively affects the cartilage structure. Indeed, by preserving the subchondral bone structure, the tissue will be less prone to microcracks and microfractures, thus preventing the vascular invasion of the cartilage and diffusion of factors from the remodeling subchondral bone. This is corroborated by the immunologic data showing that the DMM-operated EphB4-Tg mice demonstrated significantly less aggrecan and type II collagen degradation products as well as collagen disorganization.

Of note, DMM-operated EphB4-Tg mice showed a significant decrease in aggrecan cleavage in both the tibial plateau and the femoral condyle as compared to the DMM-operated WT mice, while the type II collagen degradation products as well as the decrease in collagen disorganization occurred only on the tibial plateau. A possible explanation could be that aggrecans are affected before the collagen during disease development (48–50), combined with the fact that the region at which degradation of these macromolecules takes place may vary due to differences in the mechanical stress (28, 51). Indeed, DMM surgery involves the medial displacement of the medial meniscus, resulting in weight-bearing load redistribution in a small area, leading to increased local mechanical stress. Since the mouse knee is flexed during weight bearing, there is consequently greater stress predominantly in the tibial plateau on the medial side (28).

Our findings on type X collagen further validate cartilage protection in the DMM-operated EphB4-Tg mice, as the implication of the recapitulation of growth plate–like hypertrophic differentiation of chondrocytes has been well described in the pathogenesis of cartilage degradation (52). This study clearly showed that the DMM-operated EphB4-Tg mice displayed a significantly lower level of type X collagen, thus less chondrocyte hypertrophic differentiation, than the WT mice, which is indicative of a prevention of the terminal differentiation of chondrocytes during OA in these mice. Moreover, our data showing both the reduction in type X collagen and fewer collagen degradation products, as determined with the Col2-3/4Cshort antibody, which in turn, is associated with less type II collagen, are also consistent with data suggesting that the proteolytic generation of collagen peptides may drive chondrocyte hypertrophy (53) and that proteolytically derived type II collagen fragments regulate terminal hypertrophic chondrocyte differentiation (54).

A particular feature of ephrin/Eph biology is its capacity for bidirectional signaling in which the EphB4 receptor induces a forward signaling and the ligand ephrin B2 a reverse signaling. Thus, one could question whether the effects seen in the OA subchondral bone and cartilage in this transgenic model are due to the forward and/or reverse signaling and whether this occurs through osteoclast–osteoblast and/or osteoblast–osteoblast interactions, as EphB4 was found only on the osteoblasts, but ephrin B2 on both osteoclasts and osteoblasts (18, 21, 22). With the use of the same transgenic mouse model, Zhao et al (17) demonstrated in vivo that both EphB4 forward signaling on osteoblasts and ephrin B2 reverse signaling on osteoclasts could occur, whereby the former will enhance the Dlx5, Osx, and Runx2 genes and the latter will inhibit the Fos and Nfatc1 genes. In addition, that group of investigators (17) also showed in vivo the osteoblast–osteoclast interaction leading to both forward and reverse signaling, as well as in vitro the possibility of the osteoblast–osteoblast interaction leading to EphB4 forward signaling. In studies using human OA subchondral bone osteoblasts, our group reported the presence of EphB4 forward signaling, resulting in the inhibition of the catabolic factors interleukin-1β (IL-1β), IL-6, matrix metalloproteinase 1 (MMP-1), MMP-9, MMP-13, and RANKL (22).

In conclusion, in addition to showing a protective effect of bone-specific EphB4 overexpression on subchondral bone and cartilage during OA and defining this receptor as a potential novel therapeutic avenue for the treatment of the disease, this study also provides evidence to the effect that the in vivo integrity of the overlying articular cartilage is related to the subchondral properties and that changes in the metabolism of the subchondral bone are an integral part of the OA disease process.


  1. Top of page
  2. Abstract
  7. Acknowledgements

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Martel-Pelletier had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Valverde-Franco, Pelletier, Fahmi, Matsuo, Kapoor, Martel-Pelletier.

Acquisition of data. Valverde-Franco, Hum, Lussier.

Analysis and interpretation of data. Valverde-Franco, Pelletier, Matsuo, Kapoor, Martel-Pelletier.


  1. Top of page
  2. Abstract
  7. Acknowledgements

The authors wish to express their gratitude to Frédéric Paré, Stéphane Tremblay, and François Mineau for their expert technical support and to Virginia Wallis for her assistance with the manuscript preparation. We also wish to acknowledge the professionalism of the animal care technicians at the University of Montreal Hospital Research Centre (CRCHUM). The authors are grateful to Dr. Janet E. Henderson (Director of Orthopaedic Research, McGill University, Montreal, Quebec, Canada) for sharing her expertise, and to Dr. A. Robin Poole, Dr. John S. Mort, and Dr. Eunice Lee (Shriners Hospital for Children, McGill University Hospital Centre, Montreal, Quebec, Canada) for generously providing some of the antibodies and peptides used in this project.


  1. Top of page
  2. Abstract
  7. Acknowledgements
  • 1
    Carlson CS, Loeser RF, Jayo MJ, Weaver DS, Adams MR, Jerome CP. Osteoarthritis in cynomolgus macaques: a primate model of naturally occurring disease. J Orthop Res 1994; 12: 3319.
  • 2
    Pastoureau PC, Chomel AC, Bonnet J. Evidence of early subchondral bone changes in the meniscectomized guinea pig: a densitometric study using dual-energy X-ray absorptiometry subregional analysis. Osteoarthritis Cartilage 1999; 7: 46673.
  • 3
    Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002; 46: 317884.
  • 4
    Kwan Tat S, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010; 24: 5170.
  • 5
    Hilal G, Martel-Pelletier J, Pelletier JP, Duval N, Lajeunesse D. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis Rheum 1999; 42: 211222.
  • 6
    Massicotte F, Lajeunesse D, Benderdour M, Pelletier JP, Hilal G, Duval N, et al. Can altered production of interleukin 1β, interleukin-6, transforming growth factor-β and prostaglandin E2 by isolated human subchondral osteoblasts identify two subgroups of osteoarthritic patients? Osteoarthritis Cartilage 2002; 10: 491500.
  • 7
    Massicotte F, Aubry I, Martel-Pelletier J, Pelletier JP, Fernandes J, Lajeunesse D. Abnormal insulin-like growth factor 1 signaling in human osteoarthritic subchondral bone osteoblasts. Arthritis Res Ther 2006; 8: R177.
  • 8
    Massicotte F, Fernandes JC, Martel-Pelletier J, Pelletier JP, Lajeunesse D. Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone 2006; 38: 33341.
  • 9
    Brandt KD. Insights into the natural history of osteoarthritis provided by the cruciate-deficient dog: an animal model of osteoarthritis [review]. Ann N Y Acad Sci 1994; 732: 199205.
  • 10
    Carlson CS, Loeser RF, Purser CB, Gardin JF, Jerome CP. Osteoarthritis in cynomolgus macaques. III: effects of age, gender, and subchondral bone thickness on the severity of disease. J Bone Miner Res 1996; 11: 120917.
  • 11
    Pelletier JP, Boileau C, Brunet J, Boily M, Lajeunesse D, Reboul P, et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 2004; 34: 52738.
  • 12
    Sharif M, George E, Dieppe PA. Correlation between synovial fluid markers of cartilage and bone turnover and scintigraphic scan abnormalities in osteoarthritis of the knee. Arthritis Rheum 1995; 38: 7881.
  • 13
    Petersson IF, Boegard T, Svensson B, Heinegard D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998; 37: 4650.
  • 14
    Blumenkrantz G, Lindsey CT, Dunn TC, Jin H, Ries MD, Link TM, et al. A pilot, two-year longitudinal study of the interrelationship between trabecular bone and articular cartilage in the osteoarthritic knee. Osteoarthritis Cartilage 2004; 12: 9971005.
  • 15
    Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Abram F, Choquette D, Haraoui B, et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 2008; 67: 6838.
  • 16
    Wildi LM, Raynauld JP, Martel-Pelletier J, Abram F, Dorais M, Pelletier JP. Relationship between bone marrow lesions, cartilage loss, and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI. Ann Rheum Dis 2010; 69: 211824.
  • 17
    Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006; 4: 11121.
  • 18
    Allan EH, Hausler KD, Wei T, Gooi JH, Quinn JM, Crimeen-Irwin B, et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 2008; 23: 117081.
  • 19
    Edwards CM, Mundy GR. Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int J Med Sci 2008; 5: 26372.
  • 20
    Lorenzo J. Ephs and ephrins: a new way for bone cells to communicate. J Bone Miner Res 2008; 23: 11689.
  • 21
    Matsuo K, Irie N. Osteoclast–osteoblast communication. Arch Biochem Biophys 2008; 473: 2019.
  • 22
    Kwan Tat S, Pelletier JP, Amiable N, Boileau C, Lajeunesse FD, Duval N, et al. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts: a new therapeutic approach. Arthritis Rheum 2008; 58: 382030.
  • 23
    Kwan Tat S, Pelletier JP, Amiable N, Boileau C, Lavigne M, Martel-Pelletier J. Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes. Arthritis Res Ther 2009; 11: R119.
  • 24
    Shitara H, Sato A, Hayashi J, Mizushima N, Yonekawa H, Taya C. Simple method of zygosity identification in transgenic mice by real-time quantitative PCR. Transgenic Res 2004; 13: 1914.
  • 25
    Amiable N, Martel-Pelletier J, Lussier B, Kwan Tat S, Pelletier JP, Boileau C. Proteinase-activated receptor-2 gene disruption limits the effect of osteoarthritis on cartilage in mice: a novel target in joint fegradation. J Rheumatol 2011; 38: 91120.
  • 26
    Wang G, Woods A, Agoston H, Ulici V, Glogauer M, Beier F. Genetic ablation of Rac1 in cartilage results in chondrodysplasia. Dev Biol 2007; 306: 61223.
  • 27
    Yan Q, Feng Q, Beier F. Endothelial nitric oxide synthase deficiency in mice results in reduced chondrocyte proliferation and endochondral bone growth. Arthritis Rheum 2010; 62: 201322.
  • 28
    Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage 2007; 15: 10619.
  • 29
    Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative—recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage 2010; 18 Suppl 3: S1723.
  • 30
    Drexler W, Stamper D, Jesser C, Li X, Pitris C, Saunders K, et al. Correlation of collagen organization with polarization sensitive imaging of in vitro cartilage: implications for osteoarthritis. J Rheumatol 2001; 28: 13118.
  • 31
    Vinardell T, Dejica V, Poole AR, Mort JS, Richard H, Laverty S. Evidence to suggest that cathepsin K degrades articular cartilage in naturally occurring equine osteoarthritis. Osteoarthritis Cartilage 2009; 17: 37583.
  • 32
    Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. Monoclonal antibodies that specifically recognize neoepitope sequences generated by ‘aggrecanase’ and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem J 1995; 305: 799804.
  • 33
    Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J, et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 2001; 107: 3544.
  • 34
    Lee ER, Lamplugh L, Kluczyk B, Leblond CP, Mort JS. Neoepitopes reveal the features of type II collagen cleavage and the identity of a collagenase involved in the transformation of the epiphyses anlagen in development. Dev Dyn 2009; 238: 154763.
  • 35
    Van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, van den Berg WB. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 1999; 42: 112839.
  • 36
    Valverde-Franco G, Liu H, Davidson D, Chai S, Valderrama-Carvajal H, Goltzman D, et al. Defective bone mineralization and osteopenia in young adult FGFR3−/− mice. Hum Mol Genet 2004; 13: 27184.
  • 37
    Janelle-Montcalm A, Boileau C, Poirier F, Pelletier JP, Guevremont M, Duval N, et al. Extracellular localization of galectin-3 has a deleterious role in joint tissues. Arthritis Res Ther 2007; 9: R20.
  • 38
    Grynpas MD, Alpert B, Katz I, Lieberman I, Pritzker KP. Subchondral bone in osteoarthritis. Calcif Tissue Int 1991; 49: 206.
  • 39
    Li B, Aspden RM. Composition and mechanical properties of cancellous bone from the femoral head of patients with osteoporosis or osteoarthritis. J Bone Miner Res 1997; 12: 64151.
  • 40
    Day JS, Ding M, van der Linden JC, Hvid I, Sumner DR, Weinans H. A decreased subchondral trabecular bone tissue elastic modulus is associated with pre-arthritic cartilage damage. J Orthop Res 2001; 19: 9148.
  • 41
    Day JS, van der Linden JC, Bank RA, Ding M, Hvid I, Sumner DR, et al. Adaptation of subchondral bone in osteoarthritis. Biorheology 2004; 41: 35968.
  • 42
    Couchourel D, Aubry I, Delalandre A, Lavigne M, Martel-Pelletier J, Pelletier JP, et al. Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production. Arthritis Rheum 2009; 60: 143850.
  • 43
    Botter SM, Glasson SS, Hopkins B, Clockaerts S, Weinans H, van Leeuwen JP, et al. ADAMTS5−/− mice have less subchondral bone changes after induction of osteoarthritis through surgical instability: implications for a link between cartilage and subchondral bone changes. Osteoarthritis Cartilage 2009; 17: 63645.
  • 44
    Layton MW, Goldstein SA, Goulet RW, Feldkamp LA, Kubinski DJ, Bole GG. Examination of subchondral bone architecture in experimental osteoarthritis by microscopic computed axial tomography. Arthritis Rheum 1988; 31: 14005.
  • 45
    Dedrick DK, Goldstein SA, Brandt KD, O'Connor BL, Goulet RW, Albrecht M. A longitudinal study of subchondral plate and trabecular bone in cruciate-deficient dogs with osteoarthritis followed up for 54 months. Arthritis Rheum 1993; 36: 14607.
  • 46
    Batiste DL, Kirkley A, Laverty S, Thain LM, Spouge AR, Holdsworth DW. Ex vivo characterization of articular cartilage and bone lesions in a rabbit ACL transection model of osteoarthritis using MRI and micro-CT. Osteoarthritis Cartilage 2004; 12: 98696.
  • 47
    Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA, Duong le T. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006; 38: 23443.
  • 48
    Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, et al. Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem 2003; 278: 4553945.
  • 49
    Little CB, Meeker CT, Golub SB, Lawlor KE, Farmer PJ, Smith SM, et al. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J Clin Invest 2007; 117: 162736.
  • 50
    Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 2008; 10: R63.
  • 51
    Xu L, Servais J, Polur I, Kim D, Lee PL, Chung K, et al. Attenuation of osteoarthritis progression by reduction of discoidin domain receptor 2 in mice. Arthritis Rheum 2010; 62: 273644.
  • 52
    Kawaguchi H. Regulation of osteoarthritis development by Wnt-β-catenin signaling through the endochondral ossification process. J Bone Miner Res 2009; 24: 811.
  • 53
    Tchetina EV, Kobayashi M, Yasuda T, Meijers T, Pidoux I, Poole AR. Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis. Matrix Biol 2007; 26: 24758.
  • 54
    Gauci SJ, Golub SB, Tutolo L, Little CB, Sims NA, Lee ER, et al. Modulating chondrocyte hypertrophy in growth plate and osteoarthritic cartilage. J Musculoskelet Neuronal Interact 2008; 8: 30810.